Consolidated Statements of Changes in Stockholders’ Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Stock Issuance in Connection with Emergence	Stock Issuance for Equity Rights Offering	Issuance of new common stock for the Equity Rights Offering backstop commitment	Issuance of new common stock for Bitmain obligation	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock	Common Stock Stock Issuance in Connection with Emergence	Common Stock Stock Issuance for Equity Rights Offering	Common Stock Issuance of new common stock for the Equity Rights Offering backstop commitment	Common Stock Issuance of new common stock for Bitmain obligation	Common Stock Cumulative Effect, Period of Adoption, Adjusted Balance	Additional Paid-In Capital	Additional Paid-In Capital Stock Issuance in Connection with Emergence	Additional Paid-In Capital Stock Issuance for Equity Rights Offering	Additional Paid-In Capital Issuance of new common stock for the Equity Rights Offering backstop commitment	Additional Paid-In Capital Issuance of new common stock for Bitmain obligation	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning balance (in shares) at Dec. 31, 2022								375,225
Beginning balance at Dec. 31, 2022	$ (409,346)							$ 36						$ 1,764,368						$ (2,173,750)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(388)																			(388)
Stock-based compensation	12,273													12,273
Restricted stock awards issued, net of tax withholding obligations (in shares)								2,616
Ending balance (in shares) at Mar. 31, 2023								377,841
Ending balance at Mar. 31, 2023	$ (397,461)							$ 36						1,776,641						(2,174,138)
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2023-08 [Member]
Beginning balance (in shares) at Dec. 31, 2022								375,225
Beginning balance at Dec. 31, 2022	$ (409,346)							$ 36						1,764,368						(2,173,750)
Ending balance (in shares) at Dec. 31, 2023	386,883							386,883					386,883
Ending balance at Dec. 31, 2023	$ (596,941)					$ 24	$ (596,917)	$ 36					$ 36	1,823,260					$ 1,823,260	(2,420,237)	$ 24	$ (2,420,213)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	210,691																			210,691
Stock-based compensation	(1,060)													(1,060)
Cancellation of common stock in connection with emergence (in shares)								(386,883)
Cancellation of common stock in connection with emergence	0							$ (36)						36
Issuance of new common stock in connection with emergence (in shares)									152,497	15,649	2,111	10,735
Issuance of new common stock in connection with emergence		$ 296,496	$ 55,000	$ 5,475	$ 27,839				$ 2						$ 296,494	$ 55,000	$ 5,475	$ 27,839
Conversion premium on the issuance of the New Secured Convertible Notes	33,202													33,202
Issuance of warrants	(345,856)													(345,856)
Exercise of stock options (in shares)								0
Exercise of stock options	9													9
Restricted stock awards issued, net of tax withholding obligations (in shares)								1,285
Restricted stock awards issued, net of tax withholding obligations	$ (3,388)													(3,388)
Restricted stock awards forfeited (in shares)								(40)
Ending balance (in shares) at Mar. 31, 2024	182,237							182,237
Ending balance at Mar. 31, 2024	$ (318,509)							$ 2						$ 1,891,011						$ (2,209,522)